Skip to content
value.today

Realm Therapeutics plc

Formerly Puricore plc

Total raised
$21 M
1 round on record
Latest round
$21 M
Oct 2017
First round on record
Oct 2017
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Realm Therapeutics plc
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2017$21 MNo. 1$10 to $50 million

Realm Therapeutics plc: Raise no. 1, Oct 2017

Investors in this round

8 investors had bought by the notice of Oct 25, 2017: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$21 M of $21 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
$1,230,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in United Kingdom

People named in the notice

  • Alex Martin · Executive Officer, Director
  • Marella Thorell · Executive Officer, Director
  • Balkrishan William Gill · Director
  • Charles Spicer · Director
  • Daniel William Hegglin · Director
  • Ivan William Gergel · Director
  • Joseph William Birkett · Director
  • Matthew William Hammond · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • MTS Securities, LLC (CRD 104059) · New York, New YorkSold in CA, MA, NC, NY

Signed by Marella Thorell, CFO, COO, ED & Sec'y. Source: SEC Form D and 1 amendment, newest notice filed Oct 25, 2017. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Realm Therapeutics plc had revenue of up to $1 million when it filed its newest notice of a funding round (Oct 2017).

    SEC Form D (revenue range) · Oct 2017

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Oct 2017

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Realm Therapeutics plc is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 8 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Realm Therapeutics plc
NameRoleNamed in
Alex MartinExecutive officerOct 2017
Marella ThorellExecutive officerOct 2017
Alex MartinDirectorOct 2017
Balkrishan William GillDirectorOct 2017
Charles SpicerDirectorOct 2017
Daniel William HegglinDirectorOct 2017
Ivan William GergelDirectorOct 2017
Joseph William BirkettDirectorOct 2017
Marella ThorellDirectorOct 2017
Matthew William HammondDirectorOct 2017